Designing And In-Silico Evaluation A Novel Immunotoxin For Renal Malignancies

The prevalence of cancer, lead to special attention to the developing new diagnostic andtherapeutic approaches. Among all different ways, immunotoxin therapy is known as a promisingstrategy for targeting cancerous cells. Accordingly, designing, optimization and simulation a newimmunotoxin with the ability to targeting renal malignancies have been considered in this study.Whereas, a profile of cell surface specific antigens of renal malignancies was gathered in order toselect the target. To fulfill this aim, Proteinatlas database were used for our in-silico expressionassays. Likewise, ligands of the selected antigens were detected via STRING program, and thenevaluated based on scoring and molecular docking. On the other hand, a comparative analysis onthe effective dosage of toxins was accomplished for selection toxin fragments. Moreover, Modeller,GROMACS, MOE, ERRAT, PROCHECK and Verify-3D programs were used for modeling, qualitycontrol of the structure as well as structural simulation. Bear in mind, all statistical analysis wereexpressed with SPSS 21.0 software (SPSS Inc., Chicago, IL, USA). The results of this studydemonstrate the high expression of EGFR on the renal malignancies’ cell surface. Whilst, Cetuximabwas chosen as the best coordinate ligand of the selected antigen. Furthermore, pseudomonasexotoxin A selected due to the fact of its high efficiency. Finally, the assembling of the selecteddomains with flexible liker led to design a new immunotoxin, with high stability and functionalityafter simulation, for targeting renal cancer cells. Nonetheless, the supplementary analysis forconfirming the effects of this immunotoxin is ongoing in our group.